VICL (Vical Labs) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tagore who wrote (1167)	12/21/1999 6:55:00 PM
From: WTDEC	of 1972

Tuesday December 21, 3:59 pm Eastern Time Company Press Release Vical Announces That Independent Drug Safety Review Board Recommends Continuation of Allovectin-7 Registration Trials SAN DIEGO--(BUSINESS WIRE)--Dec. 21, 1999--Vical Inc. (Nasdaq:VICL - news) announced today it will continue recruiting patients as planned in two ongoing registration trials with Allovectin-7 in patients with metastatic melanoma, based on the recommendations of an independent Drug Safety Review Board (DSRB). In a single-arm, expanded Phase II trial testing Allovectin-7 in patients with advanced metastatic melanoma, the DSRB concluded that the response rate observed to date warrants continuation of the trial. In both the Phase II trial and in a randomized, controlled Phase III trial, the DSRB found no safety issues to date that would require modification or discontinuation of either trial <snip> biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next